Insmed discontinued its brensocatib program for CRSsNP due to unmet efficacy endpoints while acquiring INS1148, a promising monoclonal antibody for respiratory and inflammatory conditions.

Target Information

Insmed Incorporated, a biopharmaceutical company based in Bridgewater, New Jersey, is focused on delivering innovative therapies for serious diseases. The company announced the results of its Phase 2b BiRCh study of brensocatib, which aimed to treat patients with chronic rhinosinusitis without nasal polyps (CRSsNP). The study involved 288 participants and examined the efficacy and safety of brensocatib compared to placebo.

Unfortunately, the results indicated that brensocatib did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms. Although the drug was well tolerated with no new safety signals reported, Insmed has decided to discontinue the development program for brensocatib in CRSsNP.

Industry Overview in the U.S.

The biopharmaceutical industry in the United States is a vital component of the healthcare system, contributing significantly to innovation and economic growth. This sector focuses on the development of therapies